HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterated a Buy rating on Armata Pharmaceuticals (AMEX:ARMP) with a maintained price target of $7.

May 08, 2024 | 1:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Armata Pharmaceuticals maintains a Buy rating and a $7 price target from HC Wainwright & Co., indicating a positive outlook.
The reiteration of a Buy rating and a maintained price target of $7 by a reputable analyst firm like HC Wainwright & Co. suggests a strong belief in the potential growth or recovery of Armata Pharmaceuticals. This endorsement could positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100